VIP for Heart Health: What the Evidence Shows
What human and animal studies show about VIP for heart health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 3
- with an outcome for heart health, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- None found
- with an outcome for heart health, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 3
- with an outcome for heart health
Evidence for heart health
Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Airway function and cardiovascular effect | At 6 pmol/kg/min infused VIP lowered systolic blood pressure from 108 to 88 mm Hg and raised heart rate from 71 to 95 beats/min, with no change in airway conductance. | Human controlled trial | Thorax 1986, PMID 3787552 |
| Pulmonary vasodilation | A single inhaled aviptadil dose had a modest, short-lived vasodilating effect with no side effects reported. | Human uncontrolled trialn = 20 | The European respiratory journal 2008, PMID 18978135 |
| Blood pressure and vasodilation | VIP infusion caused sustained vasodilatation and lowered total peripheral resistance by 30% and mean arterial pressure by 12%. | Human uncontrolled trialn = 6 | The American journal of cardiology 1987, PMID 3687785 |
VIP and heart health are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Heart disease in plain terms
MedlinePlus describes heart disease as a general term and as a type of cardiovascular disease.[4]
Cardiovascular effects measured
In six healthy subjects, VIP infusion decreased total peripheral resistance by 30% and mean arterial pressure by 12%.[3]
At 6 pmol/kg/min, infused VIP lowered systolic blood pressure from 108 to 88 mm Hg and raised heart rate from 71 to 95 beats/min in normal subjects.[1]
In patients with pulmonary hypertension, a single inhaled dose had a modest, short-lived effect on the lung vessels, with no side-effects and no change in systemic blood pressure.[2]
Other peptides people research for heart health
All peptides for heart health, comparedCommon questions
Does VIP help with heart health?
The strongest study we summarise for heart health is human rct evidence, across 3 studies with an outcome for heart health. A trial result is not an approval; see the legal status.
Is VIP approved for heart health?
No. VIP is not FDA approved for any use, including heart health.
What is the best peptide for heart health?
There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.
Is VIP good for the heart?
Cited work shows vasodilation and blood-pressure lowering in healthy people and a short-lived lung-vessel effect in pulmonary hypertension; no heart-outcome trial is cited.[3]
More on VIP
Sources
- 1Effect of infused vasoactive intestinal peptide on airway function in normal subjects.Thorax · 1986PMID 3787552Accessed 2 Oct 2026
- 2Inhalation of vasoactive intestinal peptide in pulmonary hypertension.The European respiratory journal · 2008PMID 18978135Accessed 2 Oct 2026
- 3Cardiovascular effects of vasoactive intestinal peptide in healthy subjects.The American journal of cardiology · 1987PMID 3687785Accessed 2 Oct 2026
- 4Official web pageOfficial web page · web page
Found an error? Report a correction.